Fenbendazole is a wide-ranging antiparasitic medication used in short courses (of a few days) to kill parasitic worms in dogs and other animals. It is not used long term as it can cause liver toxicity in some humans. It is also not usually taken with other drugs as it can cause drug interactions.
In a small human study it was found that fenbendazole killed cancer cells in vitro. It works by blocking the synthesis of microtubules. Microtubules are part of the cell structure and allow passage of things like chromosomes. When it blocks the synthesis of these tubules it stops mitosis, or cell division. This is similar to how some chemotherapeutic agents work.
It also inhibits the glucose uptake into malignant cells. Cancer cells consume sugar at a much higher rate than normal cells. This is known as the Warburg effect and can be seen on PET scans. Fenbendazole limits the fueling of cancer cells with glucose by blocking the uptake of sugar from the blood. It also inhibits the enzyme hexokinase 2 which is needed for glycolysis to occur.
A woman with stage 4 lung cancer started taking oral fenbendazole in July of 2019. She was taking it along with a ketogenic diet and high dose vitamin C. She was able to get her CEA down to a healthy level. Her tumor markers continued to regress. However her lungs started showing signs of inflammation, so she decided to stop the fenbendazole and start on a different regimen. fenbendazole cancer treatment
Leave a Reply